Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2017

View Archived Issues

FRMPD4 gene found to be associated with differential sex risk in multiple sclerosis

Financing to support ADC Therapeutics' pipeline of antibody-drug conjugates

Global Blood Therapeutics discontinues IPF program

Finch Therapeutics and Crestovo merge to form Finch Therapeutics Group

Favorable safety seen with AB-423 in healthy volunteers

Enanta Pharmaceuticals reports phase Ib/b trial results for lead FXR agonist

Agenus launches new subsidiary

Novel GLP-1-dexamethasone conjugates reverse immune-metabolic dysfunction and obesity

Mitochondria imaging with [18F]TAP-031 shows promise

Eisai and Biogen expand Alzheimer's collaboration agreement

FDA grants QIDP and fast track designations to Aemcolo for traveler's diarrhea

Cerveau signs license and supply agreement with AbbVie for use of [18F]MK-6240

Promising topline results from phase III ARROW study of once-weekly Kyprolis

FDA grants orphan drug status to RedHill Biopharma's Mesupron

FDA approves Soliris for AchR antibody-positive generalized myasthenia gravis

New gene therapy involving miR-132 shows promise for Huntington's disease

Topline results from phase III PEPITES study of Viaskin Peanut

GlaxoSmithKline patents hSTING modulators

Wilson Therapeutics to initiate pivotal phase III FOCuS study of WTX-101 in Wilson disease

GPR119 agonists presented by Mankind Pharma

Kitasato Institute and Sumitomo Dainippon sign antimicrobial resistance joint research agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...